Literature DB >> 17115426

Molecular dynamics studies of hexamers of amyloid-beta peptide (16-35) and its mutants: influence of charge states on amyloid formation.

Wei Han1, Yun-Dong Wu.   

Abstract

To study the early stage of amyloid-beta peptide (Abeta) aggregation, hexamers of the wild-type (WT) Abeta(16-35) and its mutants with amyloid-like conformations have been studied by molecular dynamics simulations in explicit water for a total time of 1.7 micros. We found that the amyloid-like structures in the WT oligomers are destabilized by the solvation of ionic D23/K28 residues, which are buried in the fibrils. This means that the desolvation of D23/K28 residues may contribute to the kinetic barrier of aggregation in the early stage. In the E22Q/D23N, D23N/K28Q, and E22Q/D23N/K28Q mutants, hydration becomes much less significant because the mutated residues have neutral amide side-chains. These amide side-chains can form linear cross-strand hydrogen bond chains, or "polar zippers", if dehydrated. These "polar zippers" increase the stability of the amyloid-like conformation, reducing the barrier for the early-stage oligomerization. This is in accord with experimental observations that both the D23/K28 lactamization and the E22Q/D23N mutation promote aggregation. We also found that the E22Q/D23N mutant prefers an amyloid-like conformation that differs from the one found for WT Abeta. This suggests that different amyloid structures may be formed under different conditions. 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17115426     DOI: 10.1002/prot.21232

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  10 in total

1.  Simulating oligomerization at experimental concentrations and long timescales: A Markov state model approach.

Authors:  Nicholas W Kelley; V Vishal; Grant A Krafft; Vijay S Pande
Journal:  J Chem Phys       Date:  2008-12-07       Impact factor: 3.488

2.  Comparative fibril formation of analogs corresponding to the (12-24) segment of the β-amyloid peptide.

Authors:  Luciana Malavolta; Clóvis R Nakaie
Journal:  Neurol Sci       Date:  2011-09-09       Impact factor: 3.307

3.  Self-aggregation and coaggregation of the p53 core fragment with its aggregation gatekeeper variant.

Authors:  Jiangtao Lei; Ruxi Qi; Guanghong Wei; Ruth Nussinov; Buyong Ma
Journal:  Phys Chem Chem Phys       Date:  2016-03-21       Impact factor: 3.676

4.  Conversion between parallel and antiparallel β-sheets in wild-type and Iowa mutant Aβ40 fibrils.

Authors:  Wenhui Xi; Ulrich H E Hansmann
Journal:  J Chem Phys       Date:  2018-01-28       Impact factor: 3.488

5.  Effects of oxidation, pH and lipids on amyloidogenic peptide structure: implications for fibril formation?

Authors:  Andrew Hung; Michael D W Griffin; Geoffrey J Howlett; Irene Yarovsky
Journal:  Eur Biophys J       Date:  2008-09-04       Impact factor: 1.733

6.  Molecular dynamics simulations of Alzheimer Abeta40 elongation and lateral association.

Authors:  Jie Zheng; Buyong Ma; Yung Chang; Ruth Nussinov
Journal:  Front Biosci       Date:  2008-05-01

7.  Microscopic factors that control beta-sheet registry in amyloid fibrils formed by fragment 11-25 of amyloid beta peptide: insights from computer simulations.

Authors:  Lacramioara Negureanu; Andrij Baumketner
Journal:  J Mol Biol       Date:  2009-05-03       Impact factor: 5.469

8.  Fibril elongation by Aβ(17-42): kinetic network analysis of hybrid-resolution molecular dynamics simulations.

Authors:  Wei Han; Klaus Schulten
Journal:  J Am Chem Soc       Date:  2014-08-25       Impact factor: 15.419

9.  Atomistic investigation of an Iowa Amyloid-β trimer in aqueous solution.

Authors:  Son Tung Ngo; Huong Thi Thu Phung; Khanh B Vu; Van V Vu
Journal:  RSC Adv       Date:  2018-12-13       Impact factor: 3.361

10.  Interplay of sequence, topology and termini charge in determining the stability of the aggregates of GNNQQNY mutants: a molecular dynamics study.

Authors:  Alka Srivastava; Petety V Balaji
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.